002675.SZ
002675.SZ
CNE100001DP5
DONGCHENG BIOCHEM
Loading chart...

Company Profile

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. engages in the raw materials, formulations, nuclear medicine, and big health businesses in China and internationally. It operates through API, Formulation, Radio Pharmaceutical, and Others segments. The company offers formulation products, such as powder injections, tablets, capsules, granules, and drop pills for anticoagulation, cardiovascular, anti-tumor, urology, orthopedics, and anti-infection applications. It also provides active pharmaceutical ingredients, including heparin, chondroitin sulfate sodium and calcium, hyaluronic acid, cytochrome C, and collagen, as well as glucosamine hydrochloride, glucosamine sulfate sodium chloride, and glucosamine sulfate potassium chloride; and nadroparin calcium for injection, hydrocortisone sodium succinate for injection, chorionic gonadotrophin for injection, menotropins for injection, ambroxol hydrochloride dispersible tablets, jinjunling capsules, metformin hydrochloride and glibenclamide tablets, clemastine fumarate tablets, and wind-dispelling itch-relieving granules. In addition, the company offers Technetium Methylene Diphosphonate injections; Technetium Tc=labeled tracers; 2-[18F]FDG for early diagnosis of tumors; sodium iodide oral solution; iodine seeds used for internal radiation treatment of various malignant tumors; urea capsules; and jiabaolin glucosamine chondroitin sulfate capsules. Further, it engages in trading; medical technology; medical devices; technical services; biotechnology service promotion; medical research and experimental development; business services; enterprise management, business information, and financial consulting; multimodal transport and transport agency services; capital market services; operation of local platforms for images; and engineering activities. The company exports its products to approximately 40 countries and regions. Yantai Dongcheng Pharmaceutical Group Co.,Ltd. was founded in 1998 and is headquartered in Yantai, China.

Related stocks

002020.SZ
002020.SZ • China
JINGXIN
11.87 CNY
1.53B USD 1Y -41.5%
603538.SS
603538.SS • China
NINGBO MENOVO PHARMACEUTICAL CO
28.45 CNY
1.45B USD 1Y +80%
600285.SS
600285.SS • China
HENAN LINGRUI PHARMACEUTICAL
19.66 CNY
1.67B USD 1Y -11.5%
000756.SZ
000756.SZ • China
XINHUA PHARM
14.81 CNY
1.54B USD 1Y -5.5%
600750.SS
600750.SS • China
CHINA RESOURCES JIANGZHONG PHAR
22.88 CNY
2.18B USD 1Y +3.8%
600420.SS
600420.SS • China
SHANGHAI SHYNDEC PHARMACEUTICAL
8.51 CNY
1.71B USD 1Y -20.2%
300026.SZ
300026.SZ • China
CHASE SUN PHARM.
3.32 CNY
1.49B USD 1Y -10.8%
002755.SZ
002755.SZ • China
ASK PHARM
13.34 CNY
1.85B USD 1Y -32.7%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
37.0% p.a.
Max Drawdown (5Y)
-41.8%
Sharpe Ratio (5Y)
-0.10
Beta Factor
-0.14
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 57.9 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (37.0% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -64.3% in the extended horizon.
ende